問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of Family Medicine

Division of General Internal Medicine

Division of Thoracic Medicine

China Medical University Hospital-Taipei (在職)

Division of Thoracic Medicine

更新時間：2023-09-19

杭良文Hang, Liang-wen
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

  • lungwen.hang@gmail.com

Recruiting Trial

12Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

杭良文

List

40Cases

2007-12-01 - 2009-01-22

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2007-04-01 - 2008-04-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2008-09-01 - 2009-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Terminated14Sites

2015-09-01 - 2018-04-30

Phase II

A phase IIa, randomized, double-blind, placebo controlled, parallel group study to assess the safety and efficacy of subcutaneously administered BI 655066 as add-on therapy over 24 weeks in patients with severe persistent asthma.

  • Condition/Disease

    Severe persistent asthma

  • Test Drug

    BI 655066

Participate Sites
7Sites

Terminated6Sites

2015-05-01 - 2017-03-25

Phase III

A randomized, double-blind, active drug-controlled, parallel grouping trial, in patients with severe to very severe chronic obstructive pulmonary disease (COPD), using tiotropium as a benchmark to evaluate oral inhaled tiotropium + olodaterol fixed-dose combination once a day The effect of 52-week treatment on the acute onset of COPD. [DYNAGITO]

  • Condition/Disease

    COPD

  • Test Drug

    Tiotropium + Olodaterol fixed dose combination (FDC) inhalation solution- RESPIMATR Inhaler

Participate Sites
15Sites

Terminated13Sites

鍾飲文
Kaohsiung Municipal Gangshan Hospital

未分科

鍾啟禮
Taipei Medical University Hospital

Division of Thoracic Medicine

2007-09-01 - 2009-03-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2008-10-22 - 2010-10-22

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2010-05-01 - 2013-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
15Sites

Terminated15Sites

2011-09-01 - 2013-09-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2010-02-01 - 2011-01-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Terminated13Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB